3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Myeloid
1
CNS
1
Conditions
Precursor Cell Lymphoblastic Leukemia-Lymphoma
104
Lymphoma, Large B-Cell, Diffuse
81
Leukemia, Myeloid, Acute
75
Multiple Myeloma
71
Breast Neoplasms
70
Lymphoma, Non-Hodgkin
62
Lymphoma
62
Leukemia, Lymphocytic, Chronic, B-Cell
53
Burkitt Lymphoma
53
Recurrence
51
Myelodysplastic Syndromes
50
Lymphoma, Follicular
49
Lymphoma, B-Cell
48
Leukemia
43
Triple Negative Breast Neoplasms
40
Lymphoma, Mantle-Cell
38
Neoplasms
37
Melanoma
34
Hodgkin Disease
34
Lymphoma, B-Cell, Marginal Zone
32
Hematologic Neoplasms
31
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
29
Neuroblastoma
28
Ovarian Neoplasms
26
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
22
Neoplasm Metastasis
22
Pancreatic Neoplasms
21
Leukemia, Biphenotypic, Acute
21
Sarcoma
18
Myeloproliferative Disorders
17
Interventions
Magnetic Resonance Spectroscopy
7
X-Rays
6
Specimen Handling
6
Phantoms, Imaging
6
Nuclear Medicine Department, Hospital
5
Biopsy
5
ulixertinib
2
trametinib
2
tipifarnib
2
tazemetostat
2
selpercatinib
2
palbociclib
2
larotrectinib
2
ivosidenib
2
erdafitinib
2
ensartinib
2
dabrafenib
2
LY3023414
2
olaparib
1
etoposide phosphate
1
cobimetinib
1
Vemurafenib
1
Sirolimus
1
Pharmacogenomic Variants
1
Lenalidomide
1
Genetic Testing
1
Etoposide
1
Cyclophosphamide
1
Celecoxib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Histiocytosis, Langerhans-Cell
×
Cyclophosphamide
×
1 year
×
Clear all
NCT02574728
2026-03-02
AflacST1502
Emory University
Phase 2
Active not recruiting
46 enrolled